Ghassan K. Abou‐Alfa

Verizon (United States) — United States

Medicine · Health Sciences

76h-index28.4kcitations750works8.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis(269), Cholangiocarcinoma and Gallbladder Cancer Studies(217), Pancreatic and Hepatic Oncology Research(178), Cancer Genomics and Diagnostics(117), Cancer Immunotherapy and Biomarkers(101)

Publications749 total

Gastrointestinal cancer statistics in 2022 and projection to 2050: GLOBOCAN estimates across 185 countries
Cancer·2025· 2 citedOpen Access
MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor–Resistant Cholangiocarcinoma and Attenuate the IFN Response
Clinical Cancer Research·2025Open Access
Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance)
ESMO Open·2025Open Access
Figure s2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
2025Open Access
Figure S3 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
2025Open Access
Figure S1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
2025Open Access
Figure S1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
2025Open Access
Figure S2 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
2025Open Access
supplementary legend1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
2025Open Access
Supplementary Data DS1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
2025Open Access
Supplementary Data1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
2025Open Access
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer
JAMA Oncology·2025Open Access
ASO Visual Abstract: Outcomes of First-versus Second-Line Hepatic Artery Infusion Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma
Annals of Surgical Oncology·2025
Practice changing RCT design and rationale: Abbreviated MRI plus AFP vs. ultrasound plus AFP for HCC surveillance in cirrhosis (PREMIUM study)
JHEP Reports·2025Open Access
Outcomes of First Versus Second-Line Hepatic Artery Infusion Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma
Annals of Surgical Oncology·2025
Safety of immunotherapy after liver transplantation—A multicenter study of a prospective standardized clinical practice protocol
Liver Transplantation·2025· 2 cited
Intrahepatic Cholangiocarcinoma: Recurrence Patterns, Genomics, and Survival
JCO Precision Oncology·2025
Reply: Insights into immune-mediated adverse events and survival outcomes—Lessons from HIMALAYA
Hepatology·2025
61034 Microbial Diversity Associated with Nail Toxicities in Fibroblast Growth Factor Receptor Inhibitor Treated Patients
Journal of the American Academy of Dermatology·2025
Five-year overall survival (OS) and OS by baseline liver function from the Phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Zeitschrift für Gastroenterologie·2025
page 1 of 38Next →

Frequent Co-authors

Robin Kate Kelley(13), Eileen M. O’Reilly(11), Maeve A. Lowery(10), James J. Harding(10), Mitesh J. Borad(9), Lorenza Rimassa(8), William R. Jarnagin(8), Masatoshi Kudo(7), Teresa Macarulla(7), David S. Klimstra(7), Michael F. Berger(7), Marinela Capanu(7), Anthony B. El-Khoueiry(6), Stephen L. Chan(6), Bruno Sangro(6), Milind Javle(6), Ahmet Zehir(6), Nikolaus Schultz(6), David M. Hyman(6), Do‐Youn Oh(5)